GH Research (GHRS) Short-term Investments (2020 - 2026)
GH Research (GHRS) posted quarterly Short-term Investments of $12.6 million for Q1 2025, down 75.54% year-over-year from $51.3 million in Q1 2024, and down 35.22% quarter-over-quarter from $19.4 million in Q4 2024.
Analysis
GH Research (GHRS) Short-term Investments (2020 - 2026) Analysis & Trends
GH Research's Short-term Investments history runs 5 years deep, the most recent figure standing at $12.6 million for Q1 2025.
- In Q1 2025, Short-term Investments fell 75.54% year-over-year to $12.6 million; the TTM figure through Mar 2025 stood at $12.6 million (down 75.54% YoY), while the FY2024 annual figure was $19.4 million, down 65.14% from the prior year.
- Short-term Investments for Q1 2025 stood at $12.6 million, down from $19.4 million in the prior quarter.
- The five-year high for Short-term Investments was $55.6 million in Q4 2023, with the low at $10000.0 in Q4 2021.
- The 4-year median for Short-term Investments is $46.7 million (2024), against an average of $37.8 million.
- The sharpest annual moves came in 2021 and 2025: Short-term Investments jumped 100.0% in 2021, then sank 75.54% in 2025.
- GH Research's Short-term Investments stood at $10000.0 in 2021, then jumped by 556050.0% to $55.6 million in 2023, then plunged by 65.14% to $19.4 million in 2024, then plunged by 35.22% to $12.6 million in 2025.
- Business Quant data shows GHRS's Short-term Investments at $12.6 million in Q1 2025, $19.4 million in Q4 2024, and $32.5 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.60 Mn |
| Mar 31, 2026 | 24.67 Mn |
| Dec 31, 2025 | 34.46 Mn |
| Mar 31, 2025 | 12.56 Mn |
| Dec 31, 2024 | 19.39 Mn |
| Sep 30, 2024 | 32.52 Mn |
| Jun 30, 2024 | 41.97 Mn |
| Mar 31, 2024 | 51.35 Mn |
| Dec 31, 2023 | -54.00 Mn |
| Sep 30, 2023 | 55.49 Mn |
| Jun 30, 2023 | 54.73 Mn |
| Mar 31, 2023 | 54.06 Mn |
| Dec 31, 2020 | 5,000.00 |